

Screening for Prognostic Biomarkers of Severe Bell's Palsy in Adults

NCT05582915

Status RECRUITING
Sponsor University Hospital, Montpellier
Enrollment 130 participants

Key Eligibility Criteria

Inclusion (3)

- Severe Bell's palsy (House-Brackmann more or equal to IV)
- Disease developed between 5 and 15 days before V0 (after initial corticotherapy)
- years and older

Exclusion (13)

- Facial palsy (central or peripheral) of a following cause suspected at V0:
- Diabetes, syphilis, HIV-1 or HIV-2 infection, Lyme disease, herpes zoster infection of the geniculate ganglion; Inflammatory or immune pathology, acute or chronic; Intracranial, parotid or facial nerve tumor; Craniofacial injury; Other peripheral neuropathy
- Anti-inflammatoxy, immunomodulating, immunosuppressive treatment
- Contraindications for an MRI scan
- Contraindications for a standard medical treatment: prednisone 1 mg per kg a day during 5 days and valaciclovir 3 g a day during 7 days
- ... and 8 more (see full listing online)

Locations (1 total)

CHU Montpellier, Montpellier, France